Form 4 Filing for Axsome Therapeutics, Inc. - Officer Stock Transaction

This filing reports a transaction by Hunter Murdock, General Counsel of Axsome Therapeutics, Inc. (AXSM). On April 21, 2026, Murdock was granted 7,224 Performance Stock Units (PSUs) with a transaction value of $0. The PSUs represent a contingent right to receive one share of the Issuer's common stock. Vesting of these PSUs is contingent upon the achievement of certain sales and commercial launch milestones, provided that Murdock remains in continuous service. The transaction code "A" indicates an acquisition, and the "D" in ownership nature signifies direct ownership. Following this transaction, Murdock directly owns 7,224 shares of common stock underlying the PSUs.